These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Muthu MS; Singh S Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899 [TBL] [Abstract][Full Text] [Related]
29. Recent advances on drug delivery nanocarriers for cerebral disorders. Zhou Z; Sun T; Jiang C Biomed Mater; 2021 Feb; 16(2):024104. PubMed ID: 33455956 [TBL] [Abstract][Full Text] [Related]
30. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Neganova ME; Aleksandrova YR; Sukocheva OA; Klochkov SG Semin Cancer Biol; 2022 Nov; 86(Pt 2):805-833. PubMed ID: 35779712 [TBL] [Abstract][Full Text] [Related]
31. Polymeric nanoparticles for targeted treatment in oncology: current insights. Prabhu RH; Patravale VB; Joshi MD Int J Nanomedicine; 2015; 10():1001-18. PubMed ID: 25678788 [TBL] [Abstract][Full Text] [Related]
32. Nanostructure-based drug delivery systems for brain targeting. Haque S; Md S; Alam MI; Sahni JK; Ali J; Baboota S Drug Dev Ind Pharm; 2012 Apr; 38(4):387-411. PubMed ID: 21954902 [TBL] [Abstract][Full Text] [Related]
33. Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Mohamed S; Parayath NN; Taurin S; Greish K Ther Deliv; 2014 Oct; 5(10):1101-21. PubMed ID: 25418269 [TBL] [Abstract][Full Text] [Related]
34. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art. Karim R; Palazzo C; Evrard B; Piel G J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752 [TBL] [Abstract][Full Text] [Related]
35. Polymeric nanoparticles: the future of nanomedicine. Banik BL; Fattahi P; Brown JL Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):271-99. PubMed ID: 26314803 [TBL] [Abstract][Full Text] [Related]
36. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
37. Nano-interventions for neurodegenerative disorders. Fernandes C; Soni U; Patravale V Pharmacol Res; 2010 Aug; 62(2):166-78. PubMed ID: 20153429 [TBL] [Abstract][Full Text] [Related]
38. Novel nanomaterials for clinical neuroscience. Gilmore JL; Yi X; Quan L; Kabanov AV J Neuroimmune Pharmacol; 2008 Jun; 3(2):83-94. PubMed ID: 18210200 [TBL] [Abstract][Full Text] [Related]
39. Targeting specific brain districts for advanced nanotherapies: A review from the perspective of precision nanomedicine. Sierri G; Patrucco M; Ferrario D; Renda A; Comi S; Ciprandi M; Fontanini V; Sica FS; Sesana S; Costa Verdugo M; Kravicz M; Salassa L; Busnelli M; Re F Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(5):e1991. PubMed ID: 39251878 [TBL] [Abstract][Full Text] [Related]
40. Engineered Hybrid Nanoparticles for On-Demand Diagnostics and Therapeutics. Nguyen KT; Zhao Y Acc Chem Res; 2015 Dec; 48(12):3016-25. PubMed ID: 26605438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]